Suspected Hyperviscosity or Leukostasis
Symptoms of blood hyperviscosity in hematologic malignancy
All Pathways
Hematology & OncologyEmergency
Hyperviscosity Syndrome & Leukostasis Management
Hyperviscosity Syndrome & Leukostasis Management: Suspected Hyperviscosity or Leukostasis → Determine Type of Hyperviscosity → Recognize Clinical Featur...
Pathway Overview
12 steps
Algorithm Steps
12 total
01Start 02Decision Determine Type of Hyperviscosity
Protein-mediated vs cellular
- PARAPROTEIN-MEDIATED:
- • Waldenström macroglobulinemia (IgM)
- • Multiple myeloma (IgA, IgG3)
- • Cryoglobulinemia
- CELLULAR (LEUKOSTASIS):
- • AML with WBC >100,000
- • ALL with WBC >100,000-400,000
- • CML blast crisis
03Action Recognize Clinical Features
Both types have overlapping symptoms
- NEUROLOGIC: Headache, confusion, visual changes, stupor
- VISUAL: Blurred vision, diplopia, retinal hemorrhages
- BLEEDING: Mucosal bleeding, epistaxis
- PULMONARY: Dyspnea, hypoxia (esp. leukostasis)
- CARDIAC: Heart failure symptoms
- Fundoscopy: 'sausage-link' or 'boxcar' retinal veins
04Action Paraprotein Hyperviscosity
IgM most common (Waldenström)
- Measure serum viscosity (normal 1.4-1.8 cP)
- Symptoms typically at >4-5 cP
- IgM: viscosity rises steeply with concentration
- Quantify paraprotein level
- Check cryoglobulins (keep sample warm)
05Action Plasmapheresis
First-line for paraprotein hyperviscosity
- ASFA Category I indication
- 1-1.5 plasma volume exchange
- Daily until symptoms resolve
- Uses albumin replacement (FFP if bleeding)
- Reduces IgM by 30-50% per session
- AVOID rituximab initially (IgM flare risk)
06Action Supportive Measures
For both types
- Aggressive IV hydration
- TLS prophylaxis (allopurinol/rasburicase)
- Avoid diuretics if possible
- Supplemental oxygen if hypoxic
- Monitor for DIC
- Correct coagulopathy with FFP/platelets
07Action Initiate Cytoreductive Chemotherapy
Definitive treatment for underlying disease
- LEUKOSTASIS (AML/ALL):
- • Hydroxyurea 50-75 mg/kg/day as bridge
- • Induction chemotherapy ASAP
- WALDENSTRÖM:
- • Avoid rituximab initially (IgM flare)
- • Start with BTK inhibitor or bendamustine
- MYELOMA:
- • Bortezomib-based regimen
- • Rapid reduction in paraprotein
08Action Monitor Response
Clinical and laboratory
- Symptom improvement (hours to days)
- Repeat viscosity measurements (paraprotein)
- Monitor WBC daily (leukostasis)
- Watch for tumor lysis syndrome
- Repeat apheresis if symptoms recur before chemo effect
09Outcome Hyperviscosity/Leukostasis Controlled
Continue treatment of underlying malignancy
10Action Leukostasis (Cellular)
Clinical diagnosis in hyperleukocytosis
- AML: Higher risk (larger, stickier blasts)
- • Symptomatic at WBC >100,000
- ALL: Lower risk (smaller blasts)
- • Symptomatic at WBC >200,000-400,000
- Pulmonary leukostasis: hypoxia, infiltrates
- CNS leukostasis: confusion, stroke-like symptoms
11Action Leukapheresis
Cytoreduction for leukostasis
- ASFA Category II (AML) or III (ALL) indication
- Reduces WBC by 30-60% per session
- May need 1-2 sessions
- Bridge to chemotherapy
- Limited survival benefit but reduces early mortality
- Not substitute for chemotherapy
- Path rejoins step 06Shared downstream outcome
12Warning ⚠️ AVOID RBC Transfusion
In symptomatic leukostasis
- RBC transfusion increases viscosity
- Can worsen leukostasis symptoms
- Keep Hgb <10 g/dL if symptomatic
- Transfuse only if severely anemic AND asymptomatic
Guideline Source
ASFA Guidelines for Therapeutic Apheresis + Management Reviews
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Apheresis availability varies by institution
- Leukostasis is a clinical diagnosis (no confirmatory test)
- Threshold for leukapheresis varies by leukemia type
- Avoid RBC transfusion in symptomatic leukostasis
Applicable Regions
USEU
Version 1Next review: 2027-01-11
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
Absolute Neutrophil Count (ANC)
Absolute neutrophil count from CBC for neutropenia grading
Open page
Compare
AttendMe.ai vs OpenEvidence
See how this pathway workflow compares against OpenEvidence.
Open page
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Start free
Related Resources
Frequently Asked Questions
What is the Hyperviscosity Syndrome & Leukostasis Management?
The Hyperviscosity Syndrome & Leukostasis Management is a emergency clinical algorithm for Hematology & Oncology. It provides a structured decision tree to guide clinical decision-making, based on ASFA Guidelines for Therapeutic Apheresis + Management Reviews.
What guideline is the Hyperviscosity Syndrome & Leukostasis Management based on?
This algorithm is based on ASFA Guidelines for Therapeutic Apheresis + Management Reviews (DOI: 10.1002/jca.21276).
What are the limitations of the Hyperviscosity Syndrome & Leukostasis Management?
Known limitations include: Apheresis availability varies by institution; Leukostasis is a clinical diagnosis (no confirmatory test); Threshold for leukapheresis varies by leukemia type; Avoid RBC transfusion in symptomatic leukostasis. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Hyperviscosity Syndrome & Leukostasis Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free